stoxline Quote Chart Rank Option Currency Glossary
AC Immune SA (ACIU)
4.64  0.16 (3.57%)    06-12 16:00
Open: 4.6
High: 4.75
Volume: 192,572
Pre. Close: 4.48
Low: 4.5
Market Cap: 460(M)
Technical analysis
2024-06-12 4:20:08 PM
Short term     
Mid term     
Targets 6-month :  5.81 1-year :  6.79
Resists First :  4.97 Second :  5.81
Pivot price 4.26
Supports First :  3.31 Second :  2.28
MAs MA(5) :  4.65 MA(20) :  4.03
MA(100) :  3.23 MA(250) :  3.2
MACD MACD :  0.4 Signal :  0.4
%K %D K(14,3) :  76.7 D(3) :  81
RSI RSI(14): 66.9
52-week High :  5.13 Low :  1.89
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ACIU ] has closed below upper band by 31.7%. Bollinger Bands are 62.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 19 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 4.75 - 4.78 4.78 - 4.81
Low: 4.43 - 4.47 4.47 - 4.5
Close: 4.59 - 4.64 4.64 - 4.69
Company Description

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Headline News

Tue, 11 Jun 2024
AC Immune SA (NASDAQ:ACIU) Shares Purchased by Avidity Partners Management LP - MarketBeat

Mon, 10 Jun 2024
AC Immune SA (NASDAQ:ACIU): Are Analysts Optimistic? - Yahoo Finance UK

Sun, 09 Jun 2024
Platinum Investment Management Ltd. Has $7.58 Million Holdings in AC Immune SA (NASDAQ:ACIU) - MarketBeat

Wed, 29 May 2024
Short Interest in AC Immune SA (NASDAQ:ACIU) Expands By 218.1% - Defense World

Fri, 24 May 2024
AC Immune SA's (NASDAQ:ACIU) 50% Share Price Surge Not Quite Adding Up - Simply Wall St

Tue, 21 May 2024
AC Immune SA: Progress and Promise in Neurodegenerative Disease - TipRanks

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 99 (M)
Shares Float 42 (M)
Held by Insiders 41.8 (%)
Held by Institutions 29.5 (%)
Shares Short 1,610 (K)
Shares Short P.Month 509 (K)
Stock Financials
EPS -0.69
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.46
Profit Margin 0 %
Operating Margin -379.2 %
Return on Assets (ttm) -20.9 %
Return on Equity (ttm) -36.7 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0.14
EBITDA (p.s.) -0.56
Qtrly Earnings Growth 0 %
Operating Cash Flow -43 (M)
Levered Free Cash Flow -24 (M)
Stock Valuations
PE Ratio -6.83
PEG Ratio 0
Price to Book value 3.17
Price to Sales 31
Price to Cash Flow -10.78
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android